Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani*, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J. Stone, Laura A. Petersen, Christie M. Ballantyne

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)410-412
Number of pages3
JournalCirculation
Volume139
Issue number3
DOIs
StatePublished - Jan 15 2019

Funding

This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1- 14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine. This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16-072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), an American Diabetes Association Clinical Science and Epidemiology award (1-14-CE-44), and a Houston VA Health Services Research & Development Center for Innovations Grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government, or Baylor College of Medicine.

Keywords

  • cholesterol
  • clinical trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this